First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer

阿替唑单抗 医学 紫杉醇 肿瘤科 人口 内科学 成本效益 乳腺癌 癌症 彭布罗利珠单抗 免疫疗法 环境卫生 风险分析(工程)
作者
Xiuhua Weng,Xiaoting Huang,Hongchao Li,Lin Shen,Xin Rao,Xianzhong Guo,Pinfang Huang
出处
期刊:American Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (5): 340-348 被引量:29
标识
DOI:10.1097/coc.0000000000000671
摘要

Objective: The authors conducted a cost-effectiveness analysis incorporating recent phase III clinical trial (IMpassion130) data to evaluate the cost-effectiveness of atezolizumab in combination with nab-paclitaxel (AnP) against nab-paclitaxel alone as the first-line treatment for advanced triple-negative breast cancer in developed and developing countries. Materials and Methods: A decision-analytic Markov model was developed using IMpassion130 data to evaluate the cost-effectiveness of AnP over a lifetime from the US health care payer and Chinese health care system perspective. Model inputs were derived from IMpassion130 and published literature. The primary outcomes of the model were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Uncertainty was addressed using univariate and probabilistic sensitivity analyses. Results: For the intention-to-treat (ITT) population, the projected mean outcome was better with AnP (1.41 QALYs) than with nab-paclitaxel alone (0.99 QALYs). Similar results were obtained for the programmed death ligand 1 (PD-L1)-positive population, with the obtained mean outcomes of 1.66 and 0.88 QALYs, respectively. For the Unites States, the ICER values comparing AnP with nab-paclitaxel were US$331,996.89 and US$229,359.88 per QALY gained for the ITT and PD-L1-positive populations, respectively. For China, the ICER values were US$106,339.26 and US$72,971.88 per QALY gained for the ITT and PD-L1-positive populations, respectively. The univariate sensitivity analysis indicated that the price of atezolizumab was the most influential factor in our study. AnP had 0% cost-effectiveness at the willingness-to-pay thresholds of US$150,000/QALY in the United States and US$29,383/QALY in China. Conclusion: AnP is not a cost-effective choice as the first-line treatment for advanced triple-negative breast cancer in the United States and China.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sci一区作者完成签到,获得积分20
1秒前
包容柜子发布了新的文献求助10
1秒前
hhllhh发布了新的文献求助10
2秒前
河丫应助阳洋洋采纳,获得10
2秒前
2秒前
落霞与孤鹜齐飞完成签到,获得积分10
3秒前
3秒前
3秒前
hbuhfl完成签到,获得积分10
4秒前
小瑜完成签到,获得积分10
5秒前
小蘑菇应助Lemon采纳,获得10
5秒前
betty2009完成签到,获得积分10
5秒前
星星完成签到,获得积分10
5秒前
乐观如松关注了科研通微信公众号
5秒前
6秒前
Leo发布了新的文献求助20
7秒前
7秒前
幸运星完成签到,获得积分10
7秒前
包容柜子完成签到,获得积分10
8秒前
马某发布了新的文献求助10
8秒前
123完成签到,获得积分10
8秒前
丞123完成签到,获得积分10
8秒前
花开的石头完成签到,获得积分10
9秒前
向秋完成签到,获得积分10
9秒前
刘聪聪发布了新的文献求助10
9秒前
wanci应助树下采纳,获得10
10秒前
10秒前
clm完成签到 ,获得积分10
10秒前
10秒前
10秒前
桐桐应助幸运鱼采纳,获得10
10秒前
成就的芝完成签到 ,获得积分10
10秒前
hhllhh完成签到,获得积分10
11秒前
hhh发布了新的文献求助10
14秒前
迅速曼冬发布了新的文献求助10
14秒前
15秒前
充电宝应助票子采纳,获得10
17秒前
19秒前
树下完成签到,获得积分10
20秒前
FireNow完成签到,获得积分10
21秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038426
求助须知:如何正确求助?哪些是违规求助? 3576119
关于积分的说明 11374556
捐赠科研通 3305834
什么是DOI,文献DOI怎么找? 1819339
邀请新用户注册赠送积分活动 892678
科研通“疑难数据库(出版商)”最低求助积分说明 815029